Mammoth
Preclinical Consulting

Sandra Dunn, PhD

CEO & Founder,

Phoenix Molecular Designs

“I have known Ed for over two decades and he continues to impress me. His preclinical toxicology experience is extensive and spans multiple disease verticals making him an extremely talented leader who has a proven track record in building numerous successful IND submissions to the USA FDA as we as International regulatory bodies in Europe and Asia. “

Kosalaram Goteti
Senior Scientific Director & Portfolio Section Head, Quantitative Pharmacology Merck Group

"I really enjoy working with Ed. He is scientifically sound in his M&S, PK/PD skills. In addition, He has broad experience in toxicology, ADME and pharmacology. …He guided our group to scientific excellence both internally and externally by publications, posters and presentations. He is one of those persons who gives his heart for the company, his people and the department working 24/7."

Enrique Alvarez Sotomayor, DVM, MA
Co-Founder, Sr. VP R&D
Pangolin Therapeutics

“Mammoth Preclinical Consulting offers critical and timely support in PK/PD modeling for the biotechnology sector. Mammoth uses a holistic approach that allows for the advancement of new drug candidates, with the work always focusing on the many aspects required to select a proper dose for clinical development. Ed uses his deep understanding of chemistry, biology, math and pharmacokinetics to help clients make their best decisions.”